Cancel anytime
Kura Oncology Inc (KURA)KURA
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/02/2024: KURA (3-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -4.9% | Upturn Advisory Performance 1 | Avg. Invested days: 28 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 12/02/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -4.9% | Avg. Invested days: 28 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 12/02/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 868.62M USD |
Price to earnings Ratio - | 1Y Target Price 28.57 |
Dividends yield (FY) - | Basic EPS (TTM) -2.35 |
Volume (30-day avg) 1967732 | Beta 0.86 |
52 Weeks Range 9.68 - 24.17 | Updated Date 12/2/2024 |
Company Size Small-Cap Stock | Market Capitalization 868.62M USD | Price to earnings Ratio - | 1Y Target Price 28.57 |
Dividends yield (FY) - | Basic EPS (TTM) -2.35 | Volume (30-day avg) 1967732 | Beta 0.86 |
52 Weeks Range 9.68 - 24.17 | Updated Date 12/2/2024 |
Earnings Date
Report Date 2024-11-07 | When After Market |
Estimate -0.63 | Actual -0.63 |
Report Date 2024-11-07 | When After Market | Estimate -0.63 | Actual -0.63 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.54% | Return on Equity (TTM) -46.28% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 419843800 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.48 |
Shares Outstanding 77763800 | Shares Floating 50215164 |
Percent Insiders 1.05 | Percent Institutions 108.23 |
Trailing PE - | Forward PE - | Enterprise Value 419843800 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.48 | Shares Outstanding 77763800 | Shares Floating 50215164 |
Percent Insiders 1.05 | Percent Institutions 108.23 |
Analyst Ratings
Rating 4.56 | Target Price 29.88 | Buy 3 |
Strong Buy 11 | Hold 2 | Sell - |
Strong Sell - |
Rating 4.56 | Target Price 29.88 | Buy 3 | Strong Buy 11 |
Hold 2 | Sell - | Strong Sell - |
AI Summarization
Kura Oncology Inc. (KURA): An In-Depth Look
Company Profile
History and Background
Kura Oncology Inc. was founded in 2016 by a team of experienced drug developers with a focus on discovering and developing potential therapies for oncology indications with significant unmet medical needs. The company's initial research focused on menin-MLL inhibitor programs to treat leukemia. In 2021, Kura expanded its pipeline to include a novel small molecule, tipifarnib, for the treatment of HRAS-mutant driven cancers.
Core Business Areas
Kura Oncology's core business activities encompass:
Discovery and development of novel oncology therapies: The company focuses on targeted therapies for genetically defined cancers with limited treatment options.
Clinical stage development: Kura's primary focus is on advancing its lead programs through clinical trials.
Strategic collaborations: The company actively seeks partnerships to accelerate the development and commercialization of its pipeline.
Leadership and Corporate Structure
Kura's leadership team boasts extensive experience in drug development and oncology.
Troy Wilson, Ph.D.: President and Chief Executive Officer with over 20 years of experience in the pharmaceutical industry.
Nasser Hanna, M.D.: Chief Medical Officer with deep expertise in clinical development and regulatory affairs.
Adrian Senderowicz, Ph.D.: Chief Scientific Officer with a strong record of drug discovery and development.
The company's board of directors comprises seasoned professionals from various fields, including medicine, finance, and law.
Top Products and Market Share
Key Offerings
Kura Oncology's current pipeline comprises two key programs:
Menin-MLL Inhibitor Program: This program is focused on developing first-in-class, highly selective menin-MLL inhibitors for the treatment of MLL-rearranged leukemias. The lead candidate, poziotinib, is currently in a Phase 2 clinical trial for relapsed or refractory MLL-rearranged acute myeloid leukemia (AML).
Tipifarnib program: This program explores the potential of tipifarnib, a first-in-class, orally-available farnesyltransferase inhibitor, for the treatment of advanced HRAS-mutant cancers. Tipifarnib is currently being evaluated in a Phase 2 clinical trial for HRAS-mutant bladder cancer.
Market Share Analysis
Kura Oncology's products are currently under development and have not yet been approved for commercialization. Therefore, they do not hold a market share in the global or US markets.
Total Addressable Market
Kura Oncology targets the global market for genetically defined cancers, which represents a significant unmet medical need.
MLL-rearranged leukemias: Estimated at approximately 1,000 newly diagnosed patients each year in the United States.
HRAS-mutant cancers: Estimated at approximately 180,000 newly diagnosed patients worldwide each year.
Financial Performance
Recent Financial Statements Analysis
Kura Oncology is currently in the clinical development stage and has not yet generated significant revenue. As of September 30, 2023, the company reported:
- Revenue: $0.03 million
- Net loss: $25.16 million
- Gross margin: -99.8%
- Earnings per share (EPS): -$0.63
Financial Performance Comparison
Kura Oncology is a pre-revenue company, making year-over-year comparisons of financial performance less meaningful. However, the company has consistently demonstrated progress in advancing its clinical programs and securing funding, which are positive indicators for future growth.
Cash Flow and Balance Sheet Health
As of September 30, 2023, Kura Oncology had $114.6 million in cash and cash equivalents. The company's current liabilities exceeded its current assets, resulting in a working capital deficit of $81.3 million. However, Kura has a strong runway with its existing cash resources and ongoing funding efforts.
Dividends and Shareholder Returns
Dividend History
Kura Oncology is a pre-revenue company and does not currently pay dividends.
Shareholder Returns
Kura's stock price has experienced significant volatility since its initial public offering (IPO) in 2021. Year-to-date (as of November 21, 2023), the stock has declined by approximately 50%. Over the past year, the total shareholder return has been negative.
Growth Trajectory
Historical Growth Analysis
While Kura is not yet generating revenue, it has demonstrated progress in advancing its clinical programs. The company has completed multiple clinical trials and achieved encouraging results with its lead candidates.
Future Growth Projections
Kura's future growth potential is contingent upon the successful development and commercialization of its pipeline assets. The company believes that its menin-MLL and tipifarnib programs have the potential to address significant unmet medical needs and generate substantial revenue.
Recent Initiatives for Growth
Kura is actively pursuing several initiatives to fuel its growth:
- Continuing clinical development of poziotinib and tipifarnib
- Exploring potential strategic partnerships and collaborations
- Actively seeking additional funding to support its development programs
Market Dynamics
Industry Overview
Kura operates in the highly competitive oncology market, characterized by rapid innovation and intense competition. Companies are continuously developing novel therapies and pursuing new treatment approaches for various types of cancers.
Kura's Positioning and Adaptability
Kura differentiates itself by focusing on genetically defined cancers with limited treatment options and developing first-in-class therapies. The company's adaptable approach includes strategic partnerships and a focus on clinically validated targets.
Competitors
Major Competitors and Market Share
Key competitors in Kura's target market include:
- Array BioPharma (ARRY): Market share of approximately 1% in the MLL-rearranged leukemia market.
- Mirati Therapeutics (MRTX): Market share of approximately 2% in the HRAS-mutant cancer market.
- Ionis Pharmaceuticals (IONS): Market share of approximately 3% in the oncology market.
Competitive Advantages and Disadvantages
Kura's competitive advantages include its:
- Focus on genetically defined cancers with limited treatment options
- First-in-class therapeutic candidates
- Experienced leadership team
Disadvantages include:
- Pre-revenue stage
- Limited clinical data
- Intense competition
Potential Challenges and Opportunities
Key Challenges
Kura faces several key challenges, including:
- Successfully completing clinical trials and obtaining regulatory approvals for its drug candidates
- Competing against established players in the oncology market
- Securing sufficient funding to support its development programs
Potential Opportunities
Kura has several growth opportunities, such as:
- Expanding its pipeline through strategic acquisitions or licensing agreements
- Partnering with larger pharmaceutical companies for commercialization efforts
- Leveraging its expertise in genetically defined cancers to develop novel treatment options
Recent Acquisitions
Kura Oncology has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating
Rating: 6/10
Justification:
Kura's AI-based fundamental rating of 6/10 reflects its promising pipeline, experienced leadership team, and focus on high-need areas in oncology. However, the company's pre-revenue stage, limited clinical data, and intense competition pose significant challenges. The rating acknowledges the potential for growth but reflects the inherent risk associated with early-stage, clinical-stage biopharmaceutical companies.
Sources and Disclaimers:
This analysis used information from the following sources:
- Kura Oncology Inc. investor relations website
- SEC filings
- Market research reports
Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in early-stage, clinical-stage biopharmaceutical companies involves significant risk and potential for loss. Always conduct thorough research and consult with a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kura Oncology Inc
Exchange | NASDAQ | Headquaters | San Diego, CA, United States |
IPO Launch date | 2015-09-22 | Chairman, CEO & President | Dr. Troy Edward Wilson J.D., Ph.D. |
Sector | Healthcare | Website | https://kuraoncology.com |
Industry | Biotechnology | Full time employees | 142 |
Headquaters | San Diego, CA, United States | ||
Chairman, CEO & President | Dr. Troy Edward Wilson J.D., Ph.D. | ||
Website | https://kuraoncology.com | ||
Website | https://kuraoncology.com | ||
Full time employees | 142 |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.